Orforglipron
Inventory Status:
Availability: Available
Price range: $95.00 through $145.00
Strict Regulatory Notice: This agent is synthesized strictly for laboratory-based research and analytical purposes. It is not intended for human or veterinary use, nor for medical, household, or cosmetic applications. Please review our Terms of Service thoroughly before finalizing your acquisition.
**GLP Compounds Payment Notice**
GLP compounds are not eligible for credit card purchases. When a GLP product is present in your shopping cart, all credit card payment options will be automatically removed. Please select an alternative payment method, such as ACH, Cryptocurrency, or Zelle.
Orforglipron is supplied as a high-purity analytical reference compound for non-clinical laboratory research applications.
This material is intended strictly for in-vitro biochemical and analytical studies.
Tablet Concentration 50 Tablets (~12 mg/Tablet, laboratory reference use only)
Liquid Concentration And Solution Reference solution in PEG-400 / DMSO
Nominal analytical concentration (~12 mg/mL, laboratory reference use only)
For Research Use Only. Not for human or veterinary use
Guaranteed Safe Checkout:
Key Specifications
| Parameter | Specification / Details |
|---|---|
| Primary Compound Name | Orforglipron (Non-peptide GLP-1 Receptor Agonist) |
| CAS Registry Number | 2212020-52-3 |
| IUPAC Designation | 3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one |
| Synonyms / Trade Names | LY3502970, OWL833 |
| PubChem CID | 137319706 |
| Molecular Formula | C₄₈H₄₈F₂N₁₀O₅ |
| Molar Mass / Weight | 882.97 g/mol |
| Physical Appearance | White to off-white crystalline powder (raw) / Clear liquid (suspended) |
| Solubility Profile | Soluble in DMSO (up to 125 mg/mL) and PEG 400. Insoluble in water. |
| Tested Purity | ≥98% via HPLC |
| Active Ingredient (Total) | [360mg per vial/bottle] |
| Tablet Formulations | [12mg / Tablet] |
| Liquid / Solution Concentrations | [12mg/mL in a PEG 400 / DMSO carrier] |
| Alternative Formulations | Danuglipron (closely related small-molecule GLP-1RA) |
| Storage Guidelines | Powder: Store at -20°C for long-term stability. Liquid Suspension: Store at room temperature (20°C to 25°C). Protect from moisture and light. |
| Estimated Shelf Life | 24 months from manufacture date. |
| Safety Documentation | Standard SDS available for Orforglipron |
| Terms of Application | For laboratory research purposes only. Not for human or veterinary use. Investigated as a biased ligand for the GLP-1 receptor, prioritizing G-protein activation and cyclic AMP (cAMP) accumulation over β-arrestin recruitment in cellular assays. |
| Sources https://pubchem.ncbi.nlm.nih.gov/compound/Orforglipron | |
Foundational Scientific Overview
Orforglipron is a prominent subject within the field of metabolic research and endocrinology. Originally synthesized to investigate the modulation of incretin pathways, it has become a staple for researchers examining non-peptide, orally bioavailable glucagon-like peptide-1 (GLP-1) receptor agonists.
At 4 Amino Labs, we provide this compound in a high-purity format to ensure experimental reproducibility. By maintaining rigorous measurement standards, we provide the consistency required for longitudinal data integrity. This compound is frequently cited in peer-reviewed literature due to its well-documented interaction with the GLP-1 receptor and subsequent cyclic AMP (cAMP) accumulation in pancreatic beta-cell models.
Analytical Composition & Purity Standards
- Chemical Formula: C49H50F4N10O7
- Physical State: Fine Crystalline Solid
Our Orforglipron undergoes a multifaceted verification process. Each batch is subjected to independent High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) to ensure a purity threshold of ≥ 99%. This analytical rigor ensures the absence of residual solvents, heavy metals, or cross-contaminants, providing a stable baseline for your in-vitro or pre-clinical models.
Investigational Pathways
Researchers utilizing Orforglipron typically focus on the following biochemical mechanisms:
- Receptor Kinetics: Evaluating the compound’s non-peptide binding affinity and biased agonism at the GLP-1 receptor.
- Insulinotropic Activity: Observing glucose-dependent insulin secretion pathways in isolated pancreatic islets.
- Gastric Modulation: Mapping the mechanisms of delayed gastric emptying and gastrointestinal motility in pre-clinical models.
- Cellular Viability: Investigating the agent’s role in beta-cell proliferation and resistance to apoptosis under lipotoxic stress.
Laboratory Handling & Stability Protocol
To maintain the molecular integrity of Orforglipron, the following storage parameters are recommended:
- Thermal Regulation: Store in a controlled, cool, and desiccated environment.
- Photostability: Protect from direct UV exposure; storage in an opaque container or dark cabinet is advised to prevent photodegradation.
- Hygroscopic Prevention: Ensure the seal is hermetic after every withdrawal to prevent moisture absorption and clumping.
- Contamination Control: Use sterilized instruments and work within a laminar-flow hood, when possible, to maintain sample sterility.
Compliance & Safety Disclaimer
This substance is provided exclusively for in-vitro laboratory research and pre-clinical developmental testing. 4 Amino Lab does not condone or authorize the use of this product in any clinical setting or for personal consumption. Misuse of laboratory chemicals carries significant health risks. By purchasing, the researcher acknowledges the inherent risks and confirms they possess the necessary equipment and expertise to handle these materials safely.
